Company Overview and News

 
MPO / Midstates Petroleum Company, Inc. 424B3 (Prospectus)

2018-05-02 sec.gov
Table of Contents Filed pursuant to Rule 424(b)(3)

 
MPO / Midstates Petroleum Company, Inc. DEF 14A

2018-05-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION

 
MPO / Midstates Petroleum Company, Inc. POS AM

2018-04-12 sec.gov
Table of Contents As filed with the Securities and Exchange Commission on April 12, 2018

 
Financial Exchange Stock Talk: The Turnaround Letter's Bruce Kaser On AMC Entertainment And Midstates Petroleum

2018-04-10 seekingalpha
We have begun a new partnership with Financial Exchange Radio to produce a weekly segment with Seeking Alpha authors.

 
Carl Icahn to Push for Full Board Refresh at SandRidge - WSJ

2018-04-05 wsj
Carl Icahn intends to nominate a full slate of candidates to the board of SandRidge Energy Inc., SD -0.74% saying that the current board’s overseeing a strategic review “is likely to be value destructive.”

 
Carl Icahn Will Nominate Full Sandridge Board Slate - Bloomberg

2018-04-05 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

 
MPO / Midstates Petroleum Company, Inc. POS AM

2018-03-29 sec.gov
Table of Contents As filed with the Securities and Exchange Commission on March 29, 2018

 
Oil & Gas Stock Roundup: Shell's Iraq Sale, Apache's North Sea Find & More

2018-03-27 zacks
It was a week where oil rebounded to levels not seen since January but natural gas futures settled down further.

 
For Some Wounded US Drillers, the Oil Rout Never Ended

2018-03-27 rigzone
(Bloomberg) -- More than a year after exiting bankruptcy, SandRidge Energy Inc. is stuck in stock-market purgatory.

 
For some wounded American drillers, the oil rout never ended

2018-03-27 worldoil
The oil and gas explorer has seen its stock sink 37% since October 2016, despite a restructuring that wiped out $4 billion in debt. Activist investor Carl Icahn is threatening a proxy fight, and last week SandRidge rejected a merger that would have valued the once $11-billion company at just $589 million.

 
SandRidge (SD) Nixes Merger Plan With Midstates Petroleum

2018-03-21 zacks
SandRidge Energy, Inc. (SD - Free Report) , an oil and gas player, recently aborted plans to merge with Tulsa-based rival Midstates Petroleum Company, in an all-stock deal. Last month, Midstates Petroleum had made the proposal to merge with SandRidge after the latter dropped its plan to acquire Colorado-based Bonanza, Creek Energy, Inc. (BCEI - Free Report) following intense opposition from its shareholders.

 
BlackBerry and SandRidge climb while Facebook dips

2018-03-20 nzherald.co.nz
The energy company rejected a buyout offer from Midstates Petroleum but said it will consider other offers.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 59804T407